Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;8(2):549-554.e1.
doi: 10.1016/j.jaip.2019.08.024. Epub 2019 Aug 28.

Trends and Disparities in Asthma Biologic Use in the United States

Jonathan W Inselman  1 , Molly M Jeffery  2 , Jacob T Maddux  3 , Nilay D Shah  4 , Matthew A Rank  5
Affiliations

Trends and Disparities in Asthma Biologic Use in the United States

Jonathan W Inselman et al. J Allergy Clin Immunol Pract. 2020 Feb.

Abstract

Background: From 2003 to 2015, only 1 biologic was approved for the treatment of moderate to severe asthma in the United States. Since 2015, 4 new asthma biologics were approved by the US Food and Drug Administration.

Objective: To describe trends and disparities of asthma biologic use in the United States from 2003 to 2018.

Methods: We conducted a retrospective analysis using a cohort developed from the OptumLabs Data Warehouse. Prevalent and incident asthma biologic users were identified, and characteristics of users and nonusers were analyzed using regression analysis. Clinician prescribing behavior was described.

Results: Use of biologic medications remains uncommon among individuals with asthma, with prevalence peaking in 2006 at 3 in 1000 individuals with asthma. Several factors are associated with a higher likelihood of asthma biologic use: middle age, higher income, commercial insurance, and access to a specialist. Most clinicians (65%) in the cohort prescribed only 1 biologic.

Conclusions: We report low overall use of asthma biologics and evidence of disparities in access to asthma biologics.

Keywords: Adherence; Asthma; Asthma biologics; Disparities; Trends; Utilization.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: No authors have any disclosures to make.

Figures

Figure 1.
Figure 1.
Prevalent and Incident Use of Asthma Biologics, 2003–2018
Figure 1.
Figure 1.
Prevalent and Incident Use of Asthma Biologics, 2003–2018
Figure 2.
Figure 2.
Odds ratios (adjusted) indicating likelihood of a given group being a biologic user
See this image and copyright information in PMC

References

    1. Jones K. Asthma and Injustice on Chicago’s Southeast Side. Health Aff (Millwood) 2016;35(5):928–31. - PubMed
    1. Global Initiative for Asthma. https://ginasthma.org/ Accessed March 25, 2019.
    1. Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks https://icer-review.org/wp-content/uploads/2018/04/ICER_Asthma_Final_Rep... Accessed March 26, 2019.
    1. Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in omalizumab utilization for asthma: Evidence of suboptimal patient selection. J Allergy Clin Immunol Pract 2018;6(5):1568–1577. - PubMed
    1. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health system. Health Aff (Millwood) 2014;33:1187–94. - PubMed

Publication types

Substances